PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a
2017 · Journal of Experimental & Clinical Cancer Research · 88 citations
https://doi.org/10.1186/s13046-017-0593-2
X
Xiaojia Huang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
45
Papers
1.9K
Citations
21
h-index
28
i10-index
Xiaojia Huang is an academic researcher from Huawei Technologies (China). The author has contributed to research in topics: MicroRNA in disease regulation & Cancer-related molecular mechanisms research & Breast Cancer Treatment Studies. The author has an h-index of 21, co-authored 39 publications.
Papers by this author
worksNanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma
2020 · Signal Transduction and Targeted Therapy · 66 citations
https://doi.org/10.1038/s41392-020-00248-x
Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical‐related features for axillary lymph node metastasis in early‐stage invasive breast cancer
2017 · International Journal of Cancer · 48 citations
https://doi.org/10.1002/ijc.31208
SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer
2019 · Carcinogenesis · 42 citations
https://doi.org/10.1093/carcin/bgz034
Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling
2018 · Current Cancer Drug Targets · 39 citations
https://doi.org/10.2174/1568009617666171024165657
Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
2018 · Current Cancer Drug Targets · 15 citations
https://doi.org/10.2174/1568009617666170914155355
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat